Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial) - Ahmadzadehfar, H; Rahbar, K; Baum, RP (Eur J Nucl Med Mol Imaging, 2021)
et al.